Trump administration officials are taking a hard line on high drug prices as the administration continues to put pressure on the pharmaceutical industry.
According to a New York Times report, Health and Human Services Deputy Secretary Eric Hargan told the board of the Pharmaceutical Research and Manufacturers of America that while free-market solutions are the goal, continual price increases could bring about more drastic fix.
Hargan told the board of pharmaceutical executives significant increases in insurance premiums led to increased efforts by the federal government to “review insurance premiums and other new federal regulation of health insurance.”
“That is the kind of outcome you get when major players in an American industry stop reflecting intelligently about the public good and don’t look beyond their immediate bottom line,” Hargan warned the roughly 30 CEOs in a private meeting. “I fear we’ve been seeing some of that kind of behavior in parts of the pharmaceutical industry.”